Skip to main content Accessibility help
×
Home

Endocannabinoid system and pain: an introduction

  • James J. Burston (a1) and Stephen G. Woodhams (a2)

Abstract

The endocannabinoid (EC) system consists of two main receptors: cannabinoid type 1 receptor cannabinoid receptors are found in both the central nervous system (CNS) and periphery, whereas the cannabinoid type 2 receptor cannabinoid receptor is found principally in the immune system and to a lesser extent in the CNS. The EC family consists of two classes of well characterised ligands; the N-acyl ethanolamines, such as N-arachidonoyl ethanolamide or anandamide (AEA), and the monoacylglycerols, such as 2-arachidonoyl glycerol. The various synthetic and catabolic pathways for these enzymes have been (with the exception of AEA synthesis) elucidated. To date, much work has examined the role of EC in nociceptive processing and the potential of targeting the EC system to produce analgesia. Cannabinoid receptors and ligands are found at almost every level of the pain pathway from peripheral sites, such as peripheral nerves and immune cells, to central integration sites such as the spinal cord, and higher brain regions such as the periaqueductal grey and the rostral ventrolateral medulla associated with descending control of pain. EC have been shown to induce analgesia in preclinical models of acute nociception and chronic pain states. The purpose of this review is to critically evaluate the evidence for the role of EC in the pain pathway and the therapeutic potential of EC to produce analgesia. We also review the present clinical work conducted with EC, and examine whether targeting the EC system might offer a novel target for analgesics, and also potentially disease-modifying interventions for pathophysiological pain states.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Endocannabinoid system and pain: an introduction
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Endocannabinoid system and pain: an introduction
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Endocannabinoid system and pain: an introduction
      Available formats
      ×

Copyright

Corresponding author

* Corresponding author: J. J. Burston, fax +44 (0)115 823 0142, email james.burston@nottingham.ac.uk

References

Hide All
1. Gaskin, DJ & Richard, P (2012) The economic costs of pain in the united states. J Pain 13, 715724.
2. Angst, MS & Clark, JD (2006) Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 104, 570587.
3. Mechoulam, R & Gaoni, Y (1967) Absolute configuration of delta1-tetrahydrocannabinol major active constituent of hashish. Tetrahedr Lett 8, 1109.
4. Devane, WA, Dysarz, FA, Johnson, MR et al. (1988) Determination and characterization of a cannabinoid receptor in rat-brain. Mol Pharmacol 34, 605613.
5. Herkenham, M, Lynn, AB, Little, MD et al. (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87, 19321936.
6. Herkenham, M, Lynn, AB, Johnson, MR et al. (1991) Characterization and localization of cannabinoid receptors in rat-brain - a quantitative in vitro autoradiographic study. J Neurosci 11, 563583.
7. Devane, WA, Hanus, L, Breuer, A et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 19461949.
8. Kano, M, Ohno-Shosaku, T, Hashimotodani, Y et al. (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89, 309380.
9. Katona, I & Freund, T (2012) Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 35, 529558.
10. Katona, I, Sperlagh, Bt, Sik, A et al. (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19, 45444558.
11. Egertova, M & Elphick, MR (2000) Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB1 . J Comp Neurol 422, 159171.
12. Ohno-Shosaku, T, Maejima, T & Kano, M (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29, 729738.
13. Wilson, RI & Nicoll, RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588592.
14. Di Marzo, V & De Petrocellis, L (2012) Why do cannabinoid receptors have more than one endogenous ligand? Phil Trans R Soc Lond B Biol Sci 367, 32163228.
15. Rani Sagar, D, Burston, JJ, Woodhams, SG et al. (2012) Dynamic changes to the endocannabinoid system in models of chronic pain. Phil Trans R Soc B Biol Sci 367, 33003311.
16. Galiegue, S, Mary, S, Marchand, J et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232, 5461.
17. Sagar, DR, Gaw, AG, Okine, BN et al. (2009) Dynamic regulation of the endocannabinoid system: implications for analgesia. Mol Pain 5, 59.
18. Stella, N, Schweitzer, P & Piomelli, D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773778.
19. Sugiura, T, Kondo, S, Kishimoto, S et al. (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor - comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275, 605612.
20. Zygmunt, PM, Petersson, J, Andersson, DA et al. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452457.
21. Starowicz, K & Przewlocka, B (2012) Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. Phil Trans R Soc B Biol Sci 367, 32863299.
22. Artmann, A, Petersen, G, Hellgren, LI et al. (2008) Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 1781, 200212.
23. Watanabe, S, Doshi, M & Hamazaki, T (2003) n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 69, 5159.
24. Matias, I, Gonthier, MP, Orlando, P et al. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91, 31713180.
25. Wiley, JL, Jones, AR & Wright, MJ Jr (2011) Exposure to a high-fat diet decreases sensitivity to Delta9-tetrahydrocannabinol-induced motor effects in female rats. Neuropharmacology 60, 274283.
26. Berge, K, Piscitelli, F, Hoem, N et al. (2013) Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men. Lipids Health Dis 12, 78.
27. Luchicchi, A & Pistis, M (2012) Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol 46, 374392.
28. Di Marzo, V, Fontana, A, Cadas, H et al. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686691.
29. Okamoto, Y, Morishita, J, Tsuboi, K et al. (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279, 52985305.
30. Leung, D, Saghatelian, A, Simon, GM et al. (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45, 47204726.
31. Simon, GM & Cravatt, BF (2006) Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem 281, 2646526472.
32. Simon, GM & Cravatt, BF (2008) Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem 283, 93419349.
33. Ueda, N, Tsuboi, K & Uyama, T (2010) N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog Lipid Res 49, 299315.
34. Bisogno, T, Howell, F, Williams, G et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163, 463468.
35. Dinh, TP, Carpenter, D, Leslie, FM et al. (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99, 1081910824.
36. Blankman, JL, Simon, GM & Cravatt, BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14, 13471356.
37. Loeser, JD & Treede, RD (2008) The Kyoto protocol of IASP basic pain terminology. Pain 137, 473477.
38. Basbaum, AI, Bautista, DM, Scherrer, G et al. (2009) Cellular and molecular mechanisms of pain. Cell 139, 267284.
39. Hunt, SP & Mantyh, PW (2001) The molecular dynamics of pain control. Nat Rev Neurosci 2, 8391.
40. Todd, AJ (2010) Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci 11, 823836.
41. Sagar, DR, Kendall, DA & Chapman, V (2008) Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol 155, 12971306.
42. Sagar, DR, Staniaszek, LE, Okine, BN et al. (2010) Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain. Arthritis Rheum 62, 36663676.
43. Mitrirattanakul, S, Ramakul, N, Guerrero, AV et al. (2006) Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126, 102114.
44. Chen, L, Zhang, J, Li, F et al. (2009) Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats. J Pain 10, 732739.
45. Muthian, S, Rademacher, DJ, Roelke, CT et al. (2004) Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 129, 743750.
46. Sugiura, T, Kishimoto, S, Oka, S et al. (2006) Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 45, 405446.
47. Kaplan, BL (2013) The role of CB1 in immune modulation by cannabinoids. Pharmacol Ther 137, 365374.
48. Graham, ES, Angel, CE, Schwarcz, LE et al. (2010) Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. Int J Immunopathol Pharmacol 23, 2534.
49. Pacher, P & Mechoulam, R (2011) Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50, 193211.
50. Griffin, G, Fernando, SR, Ross, RA et al. (1997) Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 339, 5361.
51. Stander, S, Schmelz, M, Metze, D et al. (2005) Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38, 177188.
52. Hohmann, AG & Herkenham, M (1999) Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90, 923931.
53. Hsieh, GC, Pai, M, Chandran, P et al. (2011) Central and peripheral sites of action for CB(2) receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol 162, 428440.
54. Zhang, F, Hong, S, Stone, V et al. (2007) Expression of cannabinoid CB1 receptors in models of diabetic neuropathy. J Pharmacol Exp Ther 323, 508515.
55. Schuelert, N, Zhang, C, Mogg, AJ et al. (2010) Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain. Osteoarthritis Cartilage 18, 15361543.
56. Tsou, K, Brown, S, Sanudo-Pena, MC et al. (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393411.
57. Farquhar-Smith, WP, Egertova, M, Bradbury, EJ et al. (2000) Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci 15, 510521.
58. Morisset, V & Urban, L (2001) Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. J Neurophysiol 86, 4048.
59. Salio, C, Doly, S, Fischer, J et al. (2002) Neuronal and astrocytic localization of the cannabinoid receptor-1 in the dorsal horn of the rat spinal cord. Neurosci Lett 329, 1316.
60. Salio, C, Fischer, J, Franzoni, MF et al. (2002) Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord. Neuroscience 110, 755764.
61. Brownjohn, PW & Ashton, JC (2012) Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury. Neuroscience 203, 180193.
62. Racz, I, Nadal, X, Alferink, J et al. (2008) Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 28, 1212512135.
63. Romero-Sandoval, A, Nutile-McMenemy, N & DeLeo, JA (2008) Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 108, 722734.
64. Alkaitis, MS, Solorzano, C, Landry, RP et al. (2010) Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain. PLoS ONE 5, e10891.
65. Berghuis, P, Dobszay, MB, Wang, X et al. (2005) Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci USA 102, 1911519120.
66. De March, Z, Zuccato, C, Giampa, C et al. (2008) Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions. Neuroscience 152, 734740.
67. Hu, H, Ho, W, Mackie, K et al. (2012) Brain CB(1) receptor expression following lipopolysaccharide-induced inflammation. Neuroscience 227, 211222.
68. Stella, N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58, 10171030.
69. Atwood, BK & Mackie, K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160, 467479.
70. Agarwal, N, Pacher, P, Tegeder, I et al. (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10, 870879.
71. Calignano, A, La Rana, G, Giuffrida, A et al. (1998) Control of pain initiation by endogenous cannabinoids. Nature 394, 277281.
72. Maione, S, De Petrocellis, L, de Novellis, V et al. (2007) Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150, 766781.
73. Beaulieu, P, Bisogno, T, Punwar, S et al. (2000) Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 396, 8592.
74. Guindon, J, Desroches, J & Beaulieu, P (2007) The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 150, 693701.
75. Jayamanne, A, Greenwood, R, Mitchell, VA et al. (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147, 281288.
76. Chang, L, Luo, L, Palmer, JA et al. (2006) Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148, 102113.
77. Lichtman, AH, Leung, D, Shelton, CC et al. (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311, 441448.
78. Kathuria, S, Gaetani, S, Fegley, D et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9, 7681.
79. Fegley, D, Gaetani, S, Duranti, A et al. (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313, 352358.
80. Russo, R, Loverme, J, La Rana, G et al. (2007) The fatty-acid amide hydrolase inhibitor URB597 (cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322, 236242.
81. Jhaveri, MD, Richardson, D, Robinson, I et al. (2008) Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55, 8593.
82. Sagar, DR, Kendall, DA & Chapman, V (2008) Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol 155, 12971306.
83. Spradley, JM, Guindon, J & Hohmann, AG (2010) Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacol Res 62, 249258.
84. Guindon, J, Guijarro, A, Piomelli, D et al. (2011) Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol 163, 14641478.
85. Clapper, JR, Moreno-Sanz, G, Russo, R et al. (2010) Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 13, 6.
86. Han, KH, Lim, S, Ryu, J et al. (2009) CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res 84, 378386.
87. Cencioni, MT, Chiurchiăą, V, Catanzaro, G et al. (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 5, e8688.
88. Samson, M-T, Small-Howard, A, Shimoda, LMN et al. (2003) Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170, 49534962.
89. Hao, M-X, Jiang, L-S, Fang, N-Y et al. (2010) The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages. J Lipid Res 51, 21812190.
90. Nomura, DK, Morrison, BE, Blankman, JL et al. (2011) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334, 809813.
91. Starowicz, K, Makuch, W, Osikowicz, M et al. (2012) Spinal anandamide produces analgesia in neuropathic rats: possible CB(1)- and TRPV1-mediated mechanisms. Neuropharmacology 62, 17461755.
92. Welch, SP, Huffman, JW & Lowe, J (1998) Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 286, 13011308.
93. Richardson, JD, Aanonsen, L & Hargreaves, KM (1997) SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 319, R3R4.
94. Chapman, V (1999) The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Br J Pharmacol 127, 17651767.
95. Sagar, DR, Jhaveri, M, Richardson, D et al. (2010) Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. Eur J Neurosci 31, 8.
96. Sagar, DR, Staniaszek, LE, Okine, BN et al. (2010) Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain. Arthritis Rheum 62, 36663676.
97. Okine, BN, Norris, LM, Woodhams, S et al. (2012) Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. Br J Pharmacol 167, 627640.
98. Petrosino, S, Palazzo, E, de Novellis, V et al. (2007) Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52, 415422.
99. Jhaveri, MD, Richardson, D, Kendall, DA et al. (2006) Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26, 1331813327.
100. Woodhams, SG, Wong, A, Barrett, DA et al. (2012) Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat. Br J Pharmacol 167, 16091619.
101. Lim, G, Sung, B, Ji, RR et al. (2003) Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105, 275283.
102. Zhang, J, Hoffert, C, Vu, HK et al. (2003) Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17, 27502754.
103. Correa, F, Docagne, F, Mestre, L et al. (2009) A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem Pharmacol 77, 86100.
104. Stella, N (2009) Endocannabinoid signaling in microglial cells. Neuropharmacology 56, Suppl. 1, 244253.
105. Walter, L, Franklin, A, Witting, A et al. (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23, 13981405.
106. Bilkei-Gorzo, A (2012) The endocannabinoid system in normal and pathological brain ageing. Phil Trans R Soc Lond B Biol Sci 367, 33263341.
107. Martin, WJ, Patrick, SL, Coffin, PO et al. (1995) An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci 56, 21032109.
108. Walker, JM, Huang, SM, Strangman, NM et al. (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96, 1219812203.
109. Rea, K, Roche, M & Finn, DP (2007) Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br J Pharmacol 152, 633648.
110. Maione, S, Bisogno, T, de Novellis, V et al. (2006) Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exper Ther 316, 969982.
111. Hohmann, AG, Suplita, RL, Bolton, NM et al. (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435, 11081112.
112. Suplita, RL II, Farthing, JN, Gutierrez, T et al. (2005) Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. Neuropharmacology 49, 12011209.
113. Suplita, RL II, Gutierrez, T, Fegley, D et al. (2006) Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology 50, 372379.
114. Gregg, LC, Jung, K-M, Spradley, JM et al. (2012) Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J Neurosci 32, 94579468.
115. Vachon-Presseau, E, Martel, M-O, Roy, M et al. (2013) Acute stress contributes to individual differences in pain and pain-related brain activity in healthy and chronic pain patients. J Neurosci 33, 68266833.
116. Rani Sagar, D, Burston, JJ, Woodhams, SG et al. (2012) Dynamic changes to the endocannabinoid system in models of chronic pain. Phil Trans R Soc Lond B Biol Sci 367, 33003311.
117. Hoot, MR, Sim-Selley, LJ, Poklis, JL et al. (2010) Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice. Brain Res 1339, 1825.
118. Sim-Selley, LJ (2003) Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15, 91119.
119. Lee, MC, Ploner, M, Wiech, K et al. (2013) Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 154, 124134.
120. Foltz, EL & White, LE (1962) Pain ‘Relief’ by frontal cingulumotomy. J Neurosurg 19, 89100.
121. Alexander, SP & Kendall, DA (2007) The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 152, 602623.
122. Fowler, CJ (2007) The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br J Pharmacol 152, 594601.
123. Kozak, KR, Crews, BC, Morrow, JD et al. (2002) Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277, 4487744885.
124. Gatta, L, Piscitelli, F, Giordano, C et al. (2012) Discovery of prostamide F2alpha and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability. PLoS ONE 7, e31111.
125. Snider, NT, Nast, JA, Tesmer, LA et al. (2009) A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist. Mol Pharmacol 75, 965972.
126. Hu, SS, Bradshaw, HB, Chen, JS et al. (2008) Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. Br J Pharmacol 153, 15381549.
127. Garcia-Merino, A (2013) Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother 13, 913.
128. Huggins, JP, Smart, TS, Langman, S et al. (2012) An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153, 18371846.
129. Ross, RA (2003) Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 140, 790801.
130. Fowler, CJ, Bjorklund, E, Lichtman, AH et al. (2013) Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide. J Enzyme Inhib Med Chem 28, 172182.
131. Windsor, MA, Hermanson, DJ, Kingsley, PJ et al. (2012) Substrate-selective inhibition of cyclooxygenase-2: development and evaluation of achiral profen probes. ACS Med Chem Lett 3, 759763.
132. Costa, B, Bettoni, I, Petrosino, S et al. (2010) The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharmacol Res 61, 537546.
133. de Novellis, V, Palazzo, E, Rossi, F et al. (2008) The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology 55, 11051113.
134. Bishay, P, Haussler, A, Lim, H-Y et al. (2013) Anandamide deficiency and heightened neuropathic pain in aged mice. Neuropharmacology 71, 204215.
135. Long, JZ, Li, WW, Booker, L et al. (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5, 3744.
136. Chang Jae, W, Niphakis Micah, J, Lum Kenneth, M et al. (2012) Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. Chem Biol 19, 579588.
137. Kinsey, SG, Wise, LE, Ramesh, D et al. (2013) Repeated low dose administration of the monoacylglycerol lipase inhibitor JZL184 retains CB1 receptor mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 345, 492501.
138. Kinsey, SG, Nomura, DK, O'Neal, ST et al. (2011) Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 338, 795802.
139. Alhouayek, M, Lambert, DM, Delzenne, NM et al. (2011) Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J 25, 27112721.

Keywords

Endocannabinoid system and pain: an introduction

  • James J. Burston (a1) and Stephen G. Woodhams (a2)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed